Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Share :
Published: 3 Jun 2025
Views: 19
Rating:
Save
Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Dr Eroglu talks to ecancer at ASCO 2025 about data she presented from the SWOG S2000 phase II trial.

This is the first randomised study in patients with symptomatic BRAF V600-mutant melanoma brain metastases (MBM) comparing the efficacy of a triplet regimen (encorafenib, binimetinib, and nivolumab) against the standard ipilimumab plus nivolumab.

The study demonstrated an improvement in 6-month progression-free survival (PFS) with the triplet (50%) versus the doublet (29%), with a hazard ratio of 0.51 (p=0.07, one-sided).

Median PFS was extended to 6.2 months with the triplet compared to 1.4 months with ipi/nivo.

Response rates and toxicity profiles favored the triplet as a promising front-line option in this challenging patient population.